Background: Limbic white matter (WM) abnormalities are prevalent in aging and Alzheimer's disease (AD), yet their underlying biological mechanisms remain unclear. This study aims to identify the genetic architecture of limbic WM microstructure in older adults by leveraging harmonized data from multiple cohorts, including those enriched for cognitively impaired individuals. Methods: We analyzed diffusion MRI (dMRI) data from 2,614 non-Hispanic White older adults (mean age = 73.7 ± 9.8 years; 57% female; 26% cognitively impaired) across 7 harmonized aging cohorts. WM microstructure was assessed in 7 limbic tracts, including the cingulum, fornix, inferior longitudinal fasciculus (ILF), uncinate fasciculus (UF), and transcallosal tracts of the inferior, middle, and superior temporal gyri (ITG, MTG, STG) using advanced diffusion MRI metrics corrected for free-water (FW): fractional anisotropy (FAFWcorr), axial diffusivity (AxDFWcorr), mean diffusivity (MDFWcorr), radial diffusivity (RDFWcorr). We performed heritability estimations, genome-wide association studies (GWAS) and post-GWAS analyses (genetic covariance, gene-level and pathway analysis, transcriptome-wide association [TWAS] studies). The AD relevance of the discovered variants was explored using bulk RNA-seq data from caudate, dorsolateral prefrontal, and posterior cingulate cortex human brain tissues. Results: Limbic WM microstructure demonstrated significant heritability (estimates between 0.26 and 0.60, pFDR < 0.05 for 15 of 35 tract-by-microstructure combinations). GWAS identified 6 genome-wide significant loci (p < 5.0x10-8) associated with WM microstructure. Notably, for MTG RDFWcorr, we identified a locus on chromosome 18 (lead SNP: rs12959877) comprising 38 SNPs that are eQTLs for CDH19, a gene involved in cell adhesion and highly expressed in oligodendrocytes. Other significant associations involved SNPs near KC6, SENP5, RORA, FAM107B, and MIR548A1. Bulk RNA-seq analyses revealed that brain tissue expression of RORA, FAM107B, and KC6 was significantly associated with cognitive decline and several AD pathologies (pFDR < 0.05). Post-GWAS analyses identified the genes SERPINA12 and DNAJB14, and highlighted the involvement of insulin signaling, immune response, and neurotrophic pathways. Genetic covariance analyses indicated shared genetic architecture between limbic WM and lipid profiles (e.g., HDL cholesterol), cardiovascular traits, and neurological conditions (e.g., multiple sclerosis) (pFDR < 0.05). Conclusion: This multi-cohort imaging genetics study identified several novel genes and biological pathways associated with limbic WM microstructure in an aging population enriched for cognitive impairment. The association of several identified genes with cognitive decline and AD pathology underscores their AD relevance. Our findings further suggest that the genetic underpinnings of limbic WM microstructure are linked to vascular health and inflammation, highlighting these pathways as promising avenues for future AD-related therapeutic development.

SCJ has served on advisory boards for Enigma Biomedical and ALZPath in the past two years. AJS receives support from multiple NIH grants (P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U19 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, U01 AG068057, U01 AG072177, U19 AG074879, and U24 AG074855). He has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in kind contribution of PET tracer precursor) and participated in Scientific Advisory Boards (Bayer Oncology, Eisai, Novo Nordisk, and Siemens Medical Solutions USA, Inc) and an Observational Study Monitoring Board (MESA, NIH NHLBI), as well as External Advisory Committees for multiple NIA grants. He also serves as Editor-in-Chief of Brain Imaging and Behavior, a Springer-Nature Journal.

This study was supported by several funding sources, including K01-EB032898 (KGS), R01-EB017230 (BAL) K01-AG073584 (DBA), U24-AG074855 (TJH), 75N95D22P00141 (TJH), R01-AG059716 (TJH), UL1-TR000445 and UL1-TR002243 (Vanderbilt Clinical Translational Science Award), S10-OD023680 (Vanderbilt's High-Performance Computer Cluster for Biomedical Research). The research was support in part by the Intramural Research Program of the National Institutes of Health, National Institute on Aging. Study data were obtained from the Vanderbilt Memory and Aging Project (VMAP). VMAP data were collected by Vanderbilt Memory and Alzheimer's Center Investigators at Vanderbilt University Medical Center. This work was supported by NIA grants R01-AG034962 (PI: Jefferson), R01-AG056534 (PI: Jefferson), U19-AG03655 (PI:Albert) and Alzheimer's Association IIRG-08-88733 (PI: Jefferson). The data contributed from the Wisconsin Registry for Alzheimer's Prevention was supported by NIA AG021155, AG027161, AG037639, and AG054047. The BLSA is supported by the Intramural Research Program of the National Institutes of Health, National Institute on Aging. This research was supported in part by the Intramural Research Program of the National Institutes of Health, National Institute on Aging. Data collection and sharing for this project was funded (in part) by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Data contributed from MAP/ROS was supported by NIA R01AG017917, P30AG10161, P30AG072975, R01AG056405, UH2NS100599, UH3NS100599, R01AG064233, R01AG015819 and R01AG067482, and the Illinois Department of Public Health (Alzheimer's Disease Research Fund). Data can be accessed at www.radc.rush.edu. The NACC database is funded by NIA/NIH Grant U24 AG072122. NACC data are contributed by the NIA-funded ADCs : P50 AG005131 (PI James Brewer, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P50 AG005138 (PI Mary Sano, PhD), P50 AG005142 (PI Helena Chui, MD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005681 (PI John Morris, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG008051 (PI Thomas Wisniewski, MD), P50 AG008702 (PI Scott Small, MD), P30 AG010124 (PI John Trojanowski, MD, PhD), P30 AG010129 (PI Charles DeCarli, MD), P30 AG010133 (PI Andrew Saykin, PsyD), P30 AG072975 (PI Julie Schneider, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG013846 (PI Neil Kowall, MD), P30 AG013854 (PI Robert Vassar, PhD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P30 AG019610 (PI Eric Reiman, MD), P50 AG023501 (PI Bruce Miller, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P30-AG072946 (PI Linda Van Eldik, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), P30 AG035982 (PI Russell Swerdlow, MD), P50 AG047266 (PI Todd Golde, MD, PhD), P50 AG047270 (PI Stephen Strittmatter, MD, PhD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG049638 (PI Suzanne Craft, PhD), P30 AG053760 (PI Henry Paulson, MD, PhD), P30 AG066546 (PI Sudha Seshadri, MD), P20 AG068024 (PI Erik Roberson, MD, PhD), P20 AG068053 (PI Marwan Sabbagh, MD), P20 AG068077 (PI Gary Rosenberg, MD), P20 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD), P30 AG072959 (PI James Leverenz, MD). NACC data can be accessed at naccdata.org.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

For all cohorts, participants provided written informed consent, and research was conducted in accordance with approved Institutional Review Board protocols. Secondary analysis of these data was approved by the Vanderbilt University Medical School Institutional Review Board.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript